The role of amyloid-β, tau, and Apolipoprotein E ε4 in Alzheimer disease: How is the team playing?

American Journal of Neuroradiology

Volumn 34, Issue 3, 2013, Pages 511-512

  Filippi, M ^a   Canu, E ^b   Agosta, F ^b  

^a Stroke Unit   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; TAU PROTEIN;

ALZHEIMER DISEASE; HUMAN; MILD COGNITIVE IMPAIRMENT; NOTE; PATHOGENESIS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BRAIN; FEMALE; HUMANS; MALE; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 84876573256     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A3295     Document Type: Note

References (7)

1. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-28
2. Desikan RS, McEvoy LK, Thompson WK, et al. Amyloid-beta associated volume loss occurs only in the presence of phospho-tau. Ann Neurol 2011;70:657-61
3. Bendlin BB, Carlsson CM, Johnson SC, et al. CSF T-tau/Abeta (42) predicts white matter microstructure in healthy adults at risk for Alzheimer's disease. PLoS One 2012;7:e37720
4. Agosta F, Pievani M, Sala S, et al. White matter damage in Alzheimer disease and its relationship to gray matter atrophy. Radiology 2011;258:853-63
5. Canu E, Frisoni GB, Agosta F, et al. Early and late onset Alzheimer's disease patients have distinct patterns of white matter damage. Neurobiol Aging 2012;33:1023-33
6. Vemuri P, Wiste HJ, Weigand SD, et al. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol 2010;67:308-16
7. Agosta F, Vossel KA, Miller BL, et al. Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. Proc Natl Acad Sci U S A 2009;106:2018-22